DDI-DrugBank.d623.s0 >> No drug-drug interaction studies have been conducted with depo-subQ provera 104. >> 58-78
DDI-DrugBank.d623.s1 >> Aminoglutethimide administered concomitantly with depo-subQ provera 104 may significantly decrease the serum concentrations of MPA. >> 0-16,50-70,127-129
DDI-DrugBank.d623.s2 >> Laboratory Tests The pathologist should be advised of progestin therapy when relevant specimens are submitted.
DDI-DrugBank.d623.s3 >> The physician should be informed that certain endocrine and liver function tests, and blood components may be affected by progestin therapy: (a) Plasma and urinary steroid levels are decreased (e.g., progesterone, estradiol, pregnanediol, testosterone, cortisol).
DDI-DrugBank.d623.s4 >> (b) Plasma and urinary gonadotropin levels are decreased (e.g., LH, FSH).
DDI-DrugBank.d623.s5 >> (c) SHBG concentrations are decreased.
DDI-DrugBank.d623.s6 >> (d) T3-uptake values may decrease.
DDI-DrugBank.d623.s7 >> (e) There may be small changes in coagulation factors.
DDI-DrugBank.d623.s8 >> (f) Sulfobromophthalein and other liver function test values may be increased slightly.
DDI-DrugBank.d623.s9 >> (g) There may be small changes in lipid profiles.
